CanBas Co Ltd (4575)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:CanBas Co Ltd (4575) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013096
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CanBas Co Ltd (CanBas) is a clinical stage biopharmaceutical company that provides drugs. The company discovers and develops of novel therapeutics in the field of oncology targeting the cell cycle. It product under development is CBP501, a modified synthetic peptide enhancing the efficacy of cisplatin without adding toxicity. CanBas’ CBP501 is in US Phase II development for first-line treatment of late stage malignant pleural mesothelioma and non-small cell lung cancer. The company’s other drug candidates, CBS9106, an orally-active synthetic small molecule of molecular mass 420, is in preclinical stage, and CBS2400 program is currently in the lead optimization stage of development. It also develops techniques to determine the drug specific sensitivity of individual cancer from a patient. CanBas is headquartered in Numazu, Japan.

CanBas Co Ltd (4575) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CanBas Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
CanBas Enters into Research Agreement with Fujifilm 10
CanBas Enters into Research Agreement with University of Shizuoka 11
Licensing Agreements 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 13
CanBas Co Ltd – Key Competitors 14
CanBas Co Ltd – Key Employees 15
CanBas Co Ltd – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Clinical Trials 17
Feb 21, 2017: Stemline Therapeutics Provides Update on SL-801 17
May 03, 2016: Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
CanBas Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CanBas Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CanBas Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CanBas Enters into Research Agreement with Fujifilm 10
CanBas Enters into Research Agreement with University of Shizuoka 11
Stemline Therapeutics Enters into Licensing Agreement with CanBas 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 13
CanBas Co Ltd, Key Competitors 14
CanBas Co Ltd, Key Employees 15

★海外企業調査レポート[CanBas Co Ltd (4575)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cyxone AB-製薬・医療分野:企業M&A・提携分析
    Summary Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company’s lead product include T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis …
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196):企業の財務・戦略的SWOT分析
    Summary Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism …
  • Atreca Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Atreca Inc (Atreca) is a biotechnology company that develops and develops novel therapies based on the human immune response. The company develops proprietary immune repertoire capture technology that act as an engine for the discovery and development of antibody based therapeutics, diagnost …
  • Phono Solar Technology Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Phono Solar Technology Co Ltd (Phono Solar), a subsidiary of Sumec Group Corp, is a renewable energy company that manufactures and markets solar photovoltaic panels. The company offers products such as solar generator, LED lights, solar modules, glass modules, phonocube, heating and cooling …
  • Toyota Tsusho Corporation:企業の戦略・SWOT・財務分析
    Toyota Tsusho Corporation - Strategy, SWOT and Corporate Finance Report Summary Toyota Tsusho Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Shell Canada Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Shell Canada Ltd (Shell Canada) a subsidiary of Royal Dutch Shell plc is an integrated oil and gas company that offers upstream and downstream services. The company's upstream services include markets and trades natural gas and power and exploration and extraction of natural gas. Its downstr …
  • China National Materials Co Ltd:企業の戦略・SWOT・財務情報
    China National Materials Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China National Materials Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Petrochemical Industries Co:企業の戦略的SWOT分析
    Petrochemical Industries Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Cerner Corp (CERN):企業の財務・戦略的SWOT分析
    Cerner Corp (CERN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Humabs BioMed SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Humabs BioMed SA (Humabs), a subsidiary of Vir Biotechnology Inc, is an antibody therapeutics biotechnology company that discovers and develops human monoclonal antibodies. The company’s pipeline programs include Flu A virus, ebola virus, HBV, rabies virus, JCV, dengue, and others. It develo …
  • Crocs, Inc.:企業の戦略・SWOT・財務情報
    Crocs, Inc. - Strategy, SWOT and Corporate Finance Report Summary Crocs, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • University of Wollongong:企業の戦略的SWOT分析
    University of Wollongong - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Bioplus Life Sciences Private Limited:企業の戦略・SWOT・財務情報
    Bioplus Life Sciences Private Limited - Strategy, SWOT and Corporate Finance Report Summary Bioplus Life Sciences Private Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Technology Nexus AB:企業の戦略的SWOT分析
    Technology Nexus AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • N Brown Group plc:企業の戦略・SWOT・財務情報
    N Brown Group plc - Strategy, SWOT and Corporate Finance Report Summary N Brown Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • KDDI Corporation (9433):企業の財務・戦略的SWOT分析
    KDDI Corporation (9433) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • China Gas Holdings Ltd (384):電力:M&Aディール及び事業提携情報
    Summary China Gas Holdings Ltd (CGHL) is a gas operator and service provider. The company offers piped natural gas, compressed natural gas, liquid petroleum gas and liquefied natural gas. Its activities include construction and operation of gas stations, gas pipeline infrastructure facilities, gas t …
  • The Weir Group Plc (WEIR):石油・ガス:M&Aディール及び事業提携情報
    Summary The Weir Group Plc (Weir Group) is a provider of engineering solutions. The company designs and manufactures highly engineered products and services for minerals, oil and gas, and power industries. Its products and service portfolio include pressure pumping equipment, pressure control produc …
  • iRhythm Technologies Inc (IRTC):企業の財務・戦略的SWOT分析
    iRhythm Technologies Inc (IRTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • WEG SA:企業の戦略・SWOT・財務分析
    WEG SA - Strategy, SWOT and Corporate Finance Report Summary WEG SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆